dengue vaccine development in...

Post on 06-Feb-2018

219 Views

Category:

Documents

4 Downloads

Preview:

Click to see full reader

TRANSCRIPT

Dengue Vaccine Development in Indonesia

National Vaccine Research Forum Dengue Vaccine Working Group

(UNAIR, UI, UGM, NIH-RD. LIPI, EIJKMAN-IMB, BPPT, PSSP)

http://www.healthmap.org/dengue/en/

Dengue IR & CFR in Indonesia, 1988-2012

11/29/2013 2

Andi Muhaidir, Dengue Vaccine Meeting, Brazil, 9-11 April 2013

Background

• DHF is still a burden and one of health priority in Indonesia

• Vector control has not successfully prevented the outbreak

• No specific treatment for Dengue infection

• Vaccine is one of the potential alternatives in dengue prevention, but none has been established completely

11/29/2013 3

Background (2)

• All 4 types of DV exist in Indonesia

• Indonesian DV’s genotypes are different from those of other countries

• Local strain based Dengue vaccine is required

• All resources should be synergized in harmony to produce vaccine with competitive advantages

11/29/2013 4

Program Development

1.

2.

3.

4.

5.

6.

7. Vaccine development research 11/29/2013 5

Andi Muhaidir, Dengue Vaccine Meeting, Brazil, 9-11 April 2013

Road Map

Mapping 2012-2013

•Serotype & Genotype Geographic Distribution

•Genetic Characterization

•Invitro Biologic Characterization

•Selection and multiplication of Virus Isolates

Seed Virus Candidate

Selection 2013

•Immunogenicity & Antigenicity Analysis

•Candidate Strain determination based on genetic conservation

Vaccine Technology

Development 2013-2015

•Vaccine forms determination

•Adjuvant

•Animal model

Formulation and Assay

Development 2015-2018

•Stability

•Formulation

•Animal testing (mice and primates)

•Antibody Dependent Enhancement testing

Parent Seed Selection

2018-2019

•Vaccine prototypes

Seed Vaccine 2020

•Validation

•Scale up

Eijkman, Litbangkes, UI,

UnAir, UGM

Eijkman, Litbangkes, UI,

UnAir, UGM

UnAir, UI, LIPI, Litbangkes,

BPPT, Biofarma

PSSP IPB, Litbangkes, UI,

UnAir, UGM

Litbangkes, UI, UnAir, UGM,

LIPI, BPPT. Biofarma

11/29/2013 6

Mapping 2012-2013

• Serotype & Genotype Geographic Distribution

– Litbangkes, eijkman, UI, UnAir, UGM

• Genetic Characterization

– Eijkman

• Invitro Biologic Characterization

– Eijkman, UnAir, UI, UGM

• Selection and multiplication of Virus Isolates

– UnAir, UI

11/29/2013 7

IDENTIFIKASI GENOTIPE DAN KARAKTERISASI GENOME VIRUS DENGUE DI INDONESIA UNTUK PENENTUAN PROTOTIPE VIRUS BAHAN PEMBUATAN VAKSIN DENGUE BERBASIS STRAIN INDONESIA

Tedjo Sasmono1), Benediktus Yohan1),Tri Yuli Setianingsih1),Aryati2,3), Puspa Wardhani2,3), Fedik. A. Rantam3)

Dengue srotype distribution in 8 Indonesian cities kota in 2010-2012.

11/29/2013 8

IDENTIFIKASI GENOTIPE DAN KARAKTERISASI GENOME VIRUS DENGUE DI INDONESIA UNTUK PENENTUAN PROTOTIPE VIRUS BAHAN PEMBUATAN VAKSIN DENGUE BERBASIS STRAIN INDONESIA

Tedjo Sasmono1), Benediktus Yohan1),Tri Yuli Setianingsih1),Aryati2,3), Puspa Wardhani2,3), Fedik. A. Rantam3)

11/29/2013 9

Indonesian Dengue Virus genetic characteristic based on its genome sequence

Seed Virus Candidate Selection 2013

• Immunogenicity & Antigenicity Analysis

– UnAir, Eijkman

• Candidate Strain determination based on genetic conservation

– Eijkman, UI

11/29/2013 10

Vaccine Technology Development 2013-2015

• Live attenuated vaccine – UnAir, eijkman

• Inactivated vaccine – UnAir

• Recombinant Live Attenuated (Chimera) – UnAir

• DNA Vaccine – UI

• Subunit vaccine – UI, Litbangkes, BPPT, UnAir

• Adjuvant & Delivery System – LIPI, BF

• Animal model – PSSP IPB

11/29/2013 11

Formulation and Assay Development 2015-2018

• Stability

– UnAir, UI, Litbangkes, Eijkman

• Tetravalent vaccine formulation

– UI, UnAir, Litbangkes

• Animal testing (mice and primates)

– Litbangkes, PSSP IPB, UI, UnAir

• Antibody Dependent Enhancement testing

– UI, Litbangkes, UnAir, UGM

11/29/2013 12

Parent Seed Selection 2018-2019 and Seed Vaccine Development 2020

• Vaccine prototypes – Litbangkes, UnAir, UI, UGM, Eijkman, LIPI, BPPT

• Validation and Scaling up – Biofarma

11/29/2013 13

Shareholder Ministries

• Mo Research & Technology

• Mo Education & Culture

• Mo Health

• Mo Trade & Industry

• Mo Finance

• National Standardization Agency

11/29/2013 14

THANK YOU

11/29/2013 15

top related